Introduction
============

The endothelium lining all blood vessels plays an essential role in the maintenance of tissue fluid homeostasis ([@bib27]). It finely controls the permeability of the vessel wall barrier to plasma proteins and small solutes via transcellular, caveolae-mediated transcytosis and paracellular, inter-endothelial junctional (IEJ) routes. Whereas IEJs are permeant to molecules with radii of 3 nm or less, caveolae-mediated vesicle trafficking transports different-sized plasma proteins across the vascular barrier ([@bib28]). The interrelationships between paracellular and transcellular pathways are not well understood. The loss of caveolin-1 (Cav-1) results in not only disappearance of caveolar structures but also destabilization of IEJs and formation of inter-endothelial gaps ([@bib38]; [@bib30]). We surmised from these previous studies that opening of the paracellular route for albumin transport in *Cav-1*^−/−^ mice might represent a general mechanism by which Cav-1 influences IEJs and regulates junctional integrity.

In addition to the transport of plasma proteins and lipids, caveolae compartmentalize signaling molecules within lipid raft microdomains ([@bib12]). Cav-1 interacts with a variety of signaling molecules such as EGF receptor (EGFR), c-Src, phosphoinositide 3-kinase (PI3K), Gα~i~, and endothelial nitric oxide synthase (eNOS; also known as NOS type 3), and binding of proteins to Cav-1 often leads to their inactivation ([@bib29]; [@bib27]). Interestingly, eNOS inhibitors were shown to restore the increase in paracellular permeability observed in Cav-1--deficient mice ([@bib30]), which suggests that eNOS activity is required for the opening of IEJs. In the present study, we addressed mechanisms by which eNOS-dependent redox signaling, which is normally held in abeyance by binding of eNOS to Cav-1 ([@bib7]), regulates IEJ integrity and thereby the permeability of the endothelial barrier.

Results and discussion
======================

We first determined basal eNOS activity in murine lung vascular endothelial cells (MLVECs) isolated from wild-type (Wt) and *Cav-1*^−/−^ mice ([Fig. S1](http://www.jcb.org/cgi/content/full/jcb.201012129/DC1)). We observed an approximately twofold increase in eNOS phosphorylation at S^1177^ ([Fig. 1 a](#fig1){ref-type="fig"}), the Akt-1 phosphorylation site known to regulate enzymatic activity of eNOS ([@bib11]). Phosphorylation of Akt-1 at S^473^ was also increased ([Fig. 1 a](#fig1){ref-type="fig"}), which indicates marked Akt-1 activation in *Cav-1*^−/−^ endothelium. Basal nitric oxide (NO) generation determined by [l]{.smallcaps}-arginine replenishment was fourfold greater in *Cav-1*^−/−^ MLVECs ([Fig. 1 b](#fig1){ref-type="fig"}). This finding is consistent with the reported increased plasma NO concentration in Cav-1--deficient mice ([@bib30]). Nitro-[l]{.smallcaps}-arginine ([l]{.smallcaps}-NNA) treatment at an inhibitory concentration for nNOS, and eNOS prevented NO generation, whereas treatment with 1400W and *N*-propyl-[l]{.smallcaps}-arginine (NPA) in combination (at inhibitory concentrations for iNOS and nNOS) had a marginal effect ([Fig. 1 b](#fig1){ref-type="fig"}). We concluded that Cav-1 deficiency in the endothelium resulted in Akt-1 and eNOS activation and an augmented NO production, which is in agreement with the role of Cav-1 in inhibiting eNOS activity in endothelium ([@bib12]).

![**Cav-1 deficiency induces eNOS activation and AJ destabilization in endothelium.** (a) Phosphorylation of eNOS at S^1177^ and Akt-1 at S^473^ in Wt and *Cav-1*^−/−^ MLVECs; *n* = 3. Molecular mass standards are indicated next to the gel blots in kilodaltons. (b) Basal NO generation was measured in the absence or presence of [l]{.smallcaps}-NNA or NPA and 1400W in combination. Arrow, [l]{.smallcaps}-arginine replenishment. Scale bars are shown for 100 nM NO and 10 min. Bar plot, NO accumulation in a media over 20 min; mean ± SEM (error bars); \*, P \< 0.05 as compared with Wt control; *n* = 6. (c) Wt and *Cav-1*^−/−^ endothelial monolayers stained for VE-cadherin, β-catenin (green in overlays), F-actin (red), and nuclei (blue). Inter-endothelial gaps in *Cav-1*^−/−^ monolayers are indicated by arrowheads. Bar, 10 µm. (d and e) Accumulation of β-catenin at AJs was expressed as a mean pixel intensity of threshold area shown in d (threshold above intracellular background is in orange). (f) Area of inter-endothelial gaps was determined using the same set of images as in e; *n* = 17. Black circles and error bars in e and f indicate mean and SEM, respectively; \*, P \< 0.01 as compared with Wt control.](JCB_201012129_RGB_Fig1){#fig1}

Next we determined the effects of Cav-1 deficiency on adherens junction (AJ) integrity, the primary adhesive complex in the continuous endothelium responsible for regulating junctional permeability. We did not observe any significant change in the expression of AJ proteins in *Cav-1*^−/−^ MLVECs compared with Wt cells (Fig. S1 b), which is in contrast to the difference reported for the brain endothelial cells ([@bib39]). This inconsistency might reflect tissue specificity (i.e., continuous vs. the highly restrictive brain endothelial barrier). Whereas AJs play a primary role in the mechanism of AJ integrity in the continuous endothelium, they are secondary in maintaining brain--blood barrier function ([@bib32]). Integrity of AJs was assessed by immunofluorescent staining for VE-cadherin, the homotypic adhesive protein of AJs ([@bib10]), and β-catenin. Both proteins accumulated at the cell border; however, clustering of VE-cadherin at the cell surface of *Cav-1*^−/−^ endothelium was markedly reduced ([Fig. 1 c](#fig1){ref-type="fig"}). VE-cadherin formed discrete patches on the *Cav-1*^−/−^ endothelial cell surface; in contrast, VE-cadherin was organized as bands encircling the Wt endothelial cells. Accumulation of β-catenin at AJs, also used to assess AJ integrity, was significantly reduced in *Cav-1*^−/−^ endothelium ([Fig. 1, c--e](#fig1){ref-type="fig"}). *Cav-1*^−/−^ monolayers were characterized by the presence of many inter-endothelial gaps ([Fig. 1, c and f](#fig1){ref-type="fig"}). [l]{.smallcaps}-NNA treatment partially restored the accumulation of β-catenin at AJs and resealed the gaps in *Cav-1*^−/−^ monolayers ([Fig. 1, c and e](#fig1){ref-type="fig"}). Although AJs remained somewhat fragmented, they appeared to assemble as bands connecting adjacent cells. Interestingly, the PI3K p110α isoform, which acts upstream of the Akt-1--eNOS signaling node, was shown to negatively regulate the integrity of AJs during inflammation by inducing the association of VE-cadherin with Pyk2 ([@bib8]). It is likely therefore that Cav-1 deficiency is also accompanied by PI3K activation, and the destabilization of VE-cadherin adhesion seen in the *Cav-1*^−/−^ monolayers might result from independent parallel signaling events. Nevertheless, our data suggest that Cav-1 modulates permeability of endothelial barrier, in part, through its negative regulation of eNOS activity.

To address mechanisms of eNOS modulation of AJ integrity, we determined the effects of NO on modification of AJ proteins. NO can lead to S-nitrosylation of cysteine, the covalent attachment of a NO group to the thiol side chain ([@bib25]), and thus influence protein function. S-nitrosylation of β-catenin was shown to facilitate destabilization of AJs in response to VEGF signaling ([@bib41]). Therefore, we determined S-nitrosothiol (SNO) content of β- and p120-catenins and of p190RhoGAP-A (referred to as p190A), a binding partner of p120-catenin ([@bib44]). We reasoned that the apparent organization of actin cytoskeleton into stress fibers in *Cav-1*^−/−^ MLVECs ([Fig. 1 c](#fig1){ref-type="fig"}) might result from insufficient control of RhoA activity. p190A, a GTPase-activating protein (GAP), facilitates RhoA-GTP hydrolysis ([@bib40]) and is a major regulator of RhoA activity at the level of AJs ([@bib26]). SNO content, determined by the biotin-switch assay ([@bib21]), of AJ proteins was indistinguishable between *Cav-1*^−/−^ and Wt endothelia, although in a control experiment we could detect SNO of β-catenin in VEGF-stimulated endothelial cells ([Fig. 2 a](#fig2){ref-type="fig"}). This finding raises the possibility that eNOS-redox signaling regulates integrity of AJs by other means.

![**Peroxynitrite generation in *Cav-1*^−/−^ endothelium and nitration of p190A.** (a) S-nitrosylation of β- and p120-catenins, and p190A. Proteins were co-immunoprecipitated with specific Abs, and precipitates were probed with HRP-avidin; results of two independent experiments are shown; *n* = 4. Note that the β-catenin band is indicated by an arrow. SNO of β-catenin in VEGF-treated cells is a positive control. Molecular mass standards are indicated next to the gel blots in kilodaltons. (b) The bar plot shows nitrite accumulation in the presence of SOD and TEMPOL; mean ± SEM (error bars); \*, P \< 0.05 as compared with Wt control; *n* = 4. (c) Bar plot shows the fluorescence emission of EOH at 580 nm; mean ± SEM (error bars); \*, P \< 0.05 as compared with Wt control; *n* = 4. (d) β- and p120-catenins and (e) p190A were co-immunoprecipitated with specific Abs, and precipitates were probed for nitrotyrosine (3-N). Results of two independent experiments are shown; *n* = 4. (e) Cav-1 deletion induced the nitration of p190A, which was reduced by TEMPOL treatment and in cells isolated from lungs of Cav-1/eNOS double knockout mice (DKO). (e, right) Bar plot; fold increase in p190A nitration normalized to p190A loading; mean ± SEM (error bars); \*, P \< 0.05 as compared with Wt; *n* = 4.](JCB_201012129_GS_Fig2){#fig2}

When NO is accompanied by O~2~^•−^ generation, it forms peroxynitrite. The diffusion-controlled reaction of NO with O~2~^•−^ is a likely source of peroxynitrite in cells and in vivo ([@bib3]; [@bib22]). The resulting peroxynitrite rapidly decomposes in the presence of ubiquitous CO~2~ to produce nitrate (NO~3~^−^) as a stable end product as well as carbonate (CO~3~^•−^) and nitrogen dioxide (^•^NO~2~) radicals ([@bib4]; [@bib1]), whose concerted action redirects peroxynitrite reactivity toward nitration of protein tyrosine residues ([@bib37]). A direct measurement of peroxynitrite in cells is precluded by the extremely short lifetime of peroxynitrite at physiological pH and by the presence of metals, reductants, and CO~2~. Because peroxynitrite formation depends on both O~2~^•−^ and NO and produces NO~3~^−^ as the only stable product after oxidant decomposition, the use of superoxide scavengers followed by measurement of nitrite (NO~2~^−^) accumulation provides an assessment of peroxynitrite formation ([@bib5]). Agents such as polyethylene glycol-superoxide dismutase (PEG-SOD) and 4-hydroxy-2,2,6,6-tetramethylpiperidinyloxy (TEMPOL) in adequate concentrations outcompete NO for O~2~^•−^, thus favoring NO autoxidation and NO~2~^−^ accumulation ([@bib19]). Here we used TEMPOL/SOD-dependent NO~2~^−^ accumulation to assess peroxynitrite formation. Both scavengers had marginal effects on accumulation of nitrite resulting from basal NO production in Wt cells ([Fig. 2 b](#fig2){ref-type="fig"}); in contrast, accumulation of nitrite was significantly higher in *Cav-1*^−/−^ cells ([Fig. 2 b](#fig2){ref-type="fig"}). Consistent with this observation, Cav-1 deficiency was accompanied by a twofold increase in O~2~^•−^ generation ([Fig. 2 c](#fig2){ref-type="fig"}), as measured by formation of 2-hydroxyethidium (EOH), a product of dihydroethidium (DHE) oxidation. Furthermore, adding tetrahydrobiopterin (BH~4~) to these cells, but not [l]{.smallcaps}-arginine, restored O~2~^•−^ generation to the level seen in Wt cells ([Fig. 2 c](#fig2){ref-type="fig"}), which suggests that BH~4~ deprivation-mediated uncoupling eNOS from NO generation is the primary mechanism of O~2~^•−^ generation in the *Cav-1*^−/−^ endothelial cells. We thus concluded that up-regulation of eNOS activity in *Cav-1*^−/−^ endothelium results in an augmented generation of both NO and O~2~^•−^ and thereby the formation of peroxynitrite.

We next determined the nitration of AJ proteins by probing immunoprecipitated proteins with anti-nitrotyrosine antibody (3-N). We failed to detect any change in nitration of either β- or p120-catenins in *Cav-1*^−/−^ endothelial monolayers ([Fig. 2 d](#fig2){ref-type="fig"}); however, nitration of p190A was significantly increased ([Fig. 2 e](#fig2){ref-type="fig"}). We also found marked reduction in p190A nitration in *Cav-1*^−/−^ endothelial cells pretreated with TEMPOL and in MLVECs isolated from lung vessels of Cav-1/eNOS double knockout mice ([Fig. 2 e](#fig2){ref-type="fig"}). Nitration of p190A also appeared to be reversible because scavenging of O~2~^•−^ significantly reduced the nitrated protein levels, although the p190A expression level itself remained unchanged ([Fig. 2 e](#fig2){ref-type="fig"}). We speculate that nitration, which in some cases targets proteins for proteolytic degradation ([@bib18]), does not regulate the metabolism and turnover of p190A. The dogma of irreversible nitration of proteins is under debate, and it is also now increasingly evident that the action of peroxynitrite might be specific ([@bib2]; [@bib15]).

Nitration compromises protein function by altering tyrosine phosphorylation ([@bib16]). The ability of p190A to hydrolyze RhoA is regulated by c-Src and FAK phosphorylation of p190A ([@bib9]; [@bib20]). Therefore, we tested whether nitration alters tyrosine phosphorylation of p190A, which could thereby inhibit its GAP activity. We found a marked decrease in p190A phosphorylation in *Cav-1*^−/−^ MLVECs ([Fig. 3 a](#fig3){ref-type="fig"}). We next addressed whether Y^1105^, the phosphorylation site critical for p190A activity ([@bib36]), might be targeted for nitration. Mutation of Y^1105^, but not Y^1087^, to phenylalanine (Y→F) prevented the chemically induced nitration of p190A by 3-morpholinosydnonimine (SIN-1; [Fig. 3 b](#fig3){ref-type="fig"}). SIN-1 also induced nitration of endogenous and transiently expressed Wt p190A but not of p190RhoGAP-B ([Fig. 3 b](#fig3){ref-type="fig"}).

![**Nitration of p190A induces RhoA activation in endothelial cells.** (a) p190A was co-immunoprecipitated and precipitates were probed for phosphotyrosine (PY20) and p190A; *n* = 3. Molecular mass standards are indicated next to the gel blots in kilodaltons. (b) Human microvascular endothelial cells (dermal) overexpressing HA-tagged p190A, p190B, or p190A mutants Y1105F and Y1087F were treated with SIN-1. Nitration of endogenous p190A and exogenously expressed proteins was determined with 3-N antibody. Exogenous proteins were co-immunoprecipitated with anti-HA antibody; *n* = 3. (c) Live imaging of a genetically encoded FRET-based RhoA biosensor. Representative YFP and FRET/CFP ratio confocal images. Pixel intensities of ratio images were scaled from 0 to 5 and color-coded as indicated on the left. Bar, 10 µm. (d) FRET/CFP emission ratio; mean and SEM are as in [Fig. 1 e](#fig1){ref-type="fig"}; *n* = 13; \*, P \< 0.01. (e) RhoA-GTP was pulled down with Rhotekin-RBD beads. Resultant precipitates and 5% of cell extracts were probed for RhoA; results of two independent experiments are shown; *n* = 4. Molecular mass standards are indicated next to the gel blots in kilodaltons.](JCB_201012129_RGB_Fig3){#fig3}

Down-regulation of p190A activity results in RhoA activation ([@bib42]), which may increase junctional permeability ([@bib20]). We thus determined whether nitration of p190A results in RhoA activation in the *Cav-1*^−/−^ endothelium. For this, we assessed RhoA activity using the FRET-based RhoA biosensor ([@bib34]). Ratio images revealed a twofold increase in RhoA activity in *Cav-1*^−/−^ monolayers compared with Wt ([Fig. 3, c and d](#fig3){ref-type="fig"}). We detected uniform RhoA activity from the edge of the cell inwards with very little and infrequent accumulation at cell edges and along extensions ([Fig. 3 c](#fig3){ref-type="fig"}), which is consistent with the distribution of active RhoA in other nonmigrating cells ([@bib34]). Notably, we observed a fourfold increase in RhoA activity by the pull-down of RhoA-GTP with Rhotekin beads ([Fig. 3 e](#fig3){ref-type="fig"}).

To demonstrate the causal link between RhoA activity and destabilization of AJs, we attempted to restore integrity of AJs in *Cav-1*^−/−^ MLVECs by inhibiting RhoA. Treatment of *Cav-1^−/−^* endothelium with the Rho inhibitor C3-transferase significantly reduced phosphorylation of myosin light chain (MLC), a downstream effector of RhoA/ROCK, in *Cav-1*^−/−^ cells ([Fig. S2](http://www.jcb.org/cgi/content/full/jcb.201012129/DC1)). It also rescued β-catenin accumulation at AJs and restored permeability of *Cav-1*^−/−^ monolayers to the Evans blue albumin (EBA) tracer ([Fig. 4, a--c](#fig4){ref-type="fig"}). Treatment of *Cav-1*^−/−^ endothelium with Cav-1 scaffold domain (CSD)--antennapedia (AP) fusion peptide, which binds to and suppresses eNOS catalytic activity ([@bib7]), superoxide scavenger TEMPOL, and [l]{.smallcaps}-NNA as well as Cav-1/eNOS deficiency (DKO) also restored the integrity of AJs and the permeability of *Cav-1*^−/−^ monolayers ([Fig. 4, a--c](#fig4){ref-type="fig"}). We concluded therefore that nitration of p190A provides a reversible switch mechanism regulating RhoA activity and thereby endothelial barrier integrity.

![**Restoration of normal paracellular permeability in *Cav-1*^−/−^ endothelial monolayers and vessels by inhibition of either RhoA or eNOS.** (a) Immunofluorescent staining of MLVECs isolated from *Cav-1*^−/−^ and Cav-1/eNOS double knockout (DKO) mice for β-catenin (green), F-actin (red), and nuclei (blue). *Cav-1*^−/−^ cells were treated with Rho inhibitor C3 transferase and AP-CSD peptide. Bar, 10 µm. (b) β-catenin accumulation at AJs as in [Fig. 1 e](#fig1){ref-type="fig"}; \*, P \< 0.01 as compared with Wt control; \*\*, P \< 0.01 as compared with *Cav-1*^−/−^; *n* = 10. (c) Endothelial permeability to EBA; mean and SEM are as in [Fig. 1 e](#fig1){ref-type="fig"}; \*, P \< 0.01 as compared with Wt control; \*\*, P \< 0.05 as compared with *Cav-1*^−/−^; *n* = 4. (d) Lung weight changes after a step increase in transvascular oncotic pressure gradient. Recordings were smoothed by averaging successive groups of five points. Lungs isolated from Wt and *Cav-1*^−/−^ mice were perfused with 0% BSA for 10 min, with 10% BSA for 30 min, and with 0% BSA for 10 min; an additional *Cav-1*^−/−^ group received AP-CSD peptide starting at 10 min of BSA profusion. AP-CSD peptide reversed lung weight loss during high albumin perfusion in *Cav-1*^−/−^ lungs and largely restored the transvascular fluid filtration rate between 40 and 50 min. (e) The filtration rate was calculated from the initial slope of slow exponential component of lung weight gain; mean and SEM are as in [Fig. 1 e](#fig1){ref-type="fig"}; \*, P \< 0.05 as compared with Wt control; *n* = 5--9.](JCB_201012129_RGB_Fig4){#fig4}

To address the role of Cav-1--eNOS interaction in the mechanism of increased paracellular permeability in vivo, we recorded fluid shift in isolated-perfused murine lungs by the gravimetric method in response to a standard perturbation of the trans-endothelial oncotic pressure gradient (π~c~--π~i~; [Fig. 4 d](#fig4){ref-type="fig"}). Elevating perfusate albumin from 0 to 10 g/100 ml caused significantly greater dehydration of lungs of *Cav-1*^−/−^ mice than in Wt control ([Fig. 4 d](#fig4){ref-type="fig"}), which indicates much faster equilibration of fluid across the endothelium devoid of Cav-1 expression. The lung weight gain (during the 40--50th min of the experiment) was fit to a double exponential function characterizing the fast and slow filtration processes ([Table S1](http://www.jcb.org/cgi/content/full/jcb.201012129/DC1)). The filtration rate calculated from the initial slope of the slow exponential component was significantly greater in *Cav-1*^−/−^ (5.5 ± 0.6 µl/min; *n* = 5) than in Wt (4.1 ± 0.3 µl/min; *n* = 9) lungs ([Fig. 4 e](#fig4){ref-type="fig"}). Perfusion with AP-CSD peptide that reanneals open IEJs ([Fig. 4 a](#fig4){ref-type="fig"}) restored transvascular fluid filtration in *Cav-1*^−/−^ lungs to the Wt values ([Fig. 4, d and e](#fig4){ref-type="fig"}). We infer therefore that Cav-1 regulates the permeability of the paracellular or AJ pathways mainly by functioning to restrain the eNOS activity.

The NO redox endothelial permeability-increasing mechanism described in this paper may contribute to deregulation of tissue fluid homeostasis during inflammation, which is known to be accompanied by loss of p190A activity and activation of RhoA ([@bib26]). Therefore, we determined whether stimulation of endothelial cell monolayers with a pro-inflammatory mediator such as the serine protease thrombin induces p190A nitration. Thrombin proteolytically cleaves and activates the protease-activated receptor PAR-1 on the endothelial surface, leading to increased intracellular calcium concentration and activation of eNOS ([@bib31]). Challenge of human pulmonary artery endothelial cells (HPAECs) with α-thrombin resulted in translocation of eNOS to AJs and a transient interaction between eNOS and p190A and nitration of p190A ([Fig. 5, a--d](#fig5){ref-type="fig"}). Nitrated p190A also remained bound to p120-catenin ([Fig. 5 d](#fig5){ref-type="fig"}). Thus, we suggest that the signaling mechanism responsible for increased vascular permeability described in this study may be important in inflammatory diseases, and hence we propose it represents a novel anti-inflammatory therapeutic target.

![**eNOS-dependent NO-redox signaling disrupts AJ integrity.** (a) Immunofluorescent staining of HPAECs for eNOS (green) and β-cat (red). DAPI (blue) is shown before and after stimulation with 50 nM α-thrombin. a1 and a2 are enlarged views of boxed regions; inter-endothelial gaps are indicated by arrowheads. Bars, 10 µm. (b) eNOS accumulation at AJs was measured as in [Fig. 1 e](#fig1){ref-type="fig"} with some modification (see Materials and methods); \*, P \< 0.05 as compared with Wt control; *n* = 6. α-Thrombin induced transient accumulation of eNOS at AJs. (c and d) α-Thrombin induced transient interaction between eNOS and p190A and nitration of p190A. eNOS and p190A were co-immunoprecipitated with specific Abs from HPAECs stimulated with 50 nM α-thrombin. Precipitates were probed for p190A, eNOS, 3-N, and p120-catenin. Molecular mass standards are indicated next to the gel blots in kilodaltons. (e) Model showing that Cav-1--mediated recruitment of eNOS into caveolar domain allows formation of stable endothelial VE-cadherin adhesions, which restricts the permeability of the paracellular route to plasma proteins. Deficiency in Cav-1 or release of eNOS from caveolae results in activation of eNOS, translocation of eNOS to AJs, and transient interaction with p190A. Peroxynitrite, a product of NO and O~2~^•−^, inhibits p190A activity by nitrating Y^1105^. Activation of RhoA leads to reorganization of the actin cytoskeleton, actomyosin contractility, destabilization of AJs, and increased vascular permeability via the paracellular pathway.](JCB_201012129R_RGB_Fig5){#fig5}

In conclusion, our study demonstrates that paracellular permeability of the endothelium is finely regulated by constitutive Cav-1--dependent inhibition of eNOS activity ([Fig. 5 e](#fig5){ref-type="fig"}). Deficiency in Cav-1 or activation of eNOS in conjunction with O~2~^•−^ production results in nitration of p190A and the concomitant activation of RhoA, which induces AJ destabilization and increased endothelial permeability. Because of the causal relationship of eNOS-specific signaling to the impairment of p190A activity, this mechanism induces RhoA activation in endothelial cells. In fibroblasts, however, Cav-1 depletion induces Src-dependent activation of p190A, resulting in loss of cell polarity and impaired wound healing ([@bib17]). In contrast, in endothelial cells, Cav-1 knockdown increases directional migration ([@bib14]); thus, our findings help to inform the unique role of Cav-1 expression on p190A activity in endothelial cells and how Cav-1 regulates the permeability of the endothelial junctional barrier.

Materials and methods
=====================

Antibodies and reagents
-----------------------

We used anti-HA (clone 16B12; Covance), anti-phosphotyrosine (PY20), and PECAM-1 (BD); anti--VE-cadherin, anti--β-actin, anti-β, and anti-p120 catenins; anti-RhoA, anti-eNOS, and anti--Cav-1 (Santa Cruz Biotechnology, Inc.); anti-p190RhoGAP (Sigma-Aldrich); anti-nitrotyrosine, anti-Akt, and anti--MLC 2; and phospho-eNOS-Ser^1177^, phospho-Akt-Ser^473^, and phospho-MLC2-Thr^18^/Ser^19^ (Cell Signaling Technology). Secondary Abs were HRP-conjugated donkey anti--mouse, anti--rabbit, and anti--goat (Jackson ImmunoResearch Laboratories, Inc.); TRITC-, FITC-, and Cy-5-conjugated donkey anti--mouse, anti--goat, and anti--rabbit (Jackson ImmunoResearch Laboratories, Inc.), Alexa Fluor 532 phalloidin, and DAPI (Sigma-Aldrich).

We used protein A/G beads (Santa Cruz Biotechnology, Inc.), DHE, and Dynabeads M-450 (Invitrogen). We also used a Rho activation assay kit and Rho inhibitor C3 transferase (Cytoskeleton), SIN-1 (EMD), NPA, [l]{.smallcaps}-NNA, and 1400W (Cayman Chemical), PEG-SOD, TEMPOL, (6R)-5,6,7,8-tetrahydrobiopterin dihydrochloride (BH4), [l]{.smallcaps}-arginine, sodium iodide, and sodium nitrite (Sigma-Aldrich), as well as AP-CSD peptide (EMD).

Expression constructs, primers, and RT-PCR
------------------------------------------

HA-tagged rat p190A and p190B, Y1105F, and Y1087F mutants of p190A were gifts from S.J. Parsons (University of Virginia, Charlottesville, VA); the RhoA biosensor was from K. Hahn (University of North Carolina at Chapel Hill, Chapel Hill, NC). The mRNA was assessed by quantitative real-time PCR ([@bib35]). Primer and probe sequences were as follows: Cav-1 forward, 5′-CAGCATGTCTGGGGGTAAAT-3′, and reverse, 5′-TGCTTCTCATTCACCTCGTCT-3′; Cav-2 forward, 5′-TGTTTCTAGCCATCCCCTTG-3′, and reverse, 5′-ACCATGAGGCAGGTCTTCAC-3′; eNOS forward, 5′-TCTGCGGCGATGTCACTATG-3′, and reverse 5′-CATGCCGCCCTCTGTTG-3′; VE-cadherin forward, 5′-GTGGATGAGCCCCCTGTCT-3′; and reverse, 5′-CAGCGGTTTCTTCTGGTTTTCT-3′; and Vw-F forward, 5′-GCTTCCAACTGAACTGTGAGACCT-3′; and reverse, 5′-GGCTGTGATGTCTTTGCAATCAG-3′. The relative mRNA expression was normalized to the 18S gene (Applied Biosystems).

Cell culture, treatments, and transfection
------------------------------------------

*Cav-1*^−/−^ and matching control mice of C57bl/6 background were obtained from The Jackson Laboratory (JAX mice and services). *Cav-1/eNOS* double knockout was produced as described previously ([@bib45]). MLVECs were isolated as described previously ([@bib13]), with some modification. In brief, 3--4-wk-old mice were anesthetized by using isoflurane (2.5% in room air) according to the protocol approved by the University of Illinois Animal Care Committee. Depth of anesthesia was ascertained by loss of pain reflex to a vigorous paw pinch. After exsanguination, the lung was perfused with sterile HBSS supplemented with antibiotics. Lung was removed, minced, and digested with collagenase A (1.0 mg/ml in HBSS) for 60 min at 37°C on shaker. The released cells were centrifuged at 200 *g* for 10 min. The pellet was suspended in 10 ml of suspension buffer (Ca^2+^- and Mg^2+^-free PBS containing 0.5 g/100 ml bovine serum albumin, 2 mM EDTA, and 4.5 mg/ml [d]{.smallcaps}-glucose), and filtered through a 200-µm mesh sterile filter. The cell suspension was incubated with 10 µg of anti--mouse PECAM-1 antibody on ice for 1 h, centrifuged to remove unbound antibody, and washed once with suspension buffer. The cells were incubated with Dynabeads M-450 (Sheep anti-rat IgG) for 60 min at 4°C. The cells attached to Dynabeads were trapped in a magnetic column to separate a subpopulation of PECAM-1--positive cells, washed, and resuspended in endothelial growth medium EGM-2 MV medium (Lonza), supplemented with 10% FBS (Invitrogen), and seeded in Matrigel-coated culture dishes (BD).

MLVECs and human lung microvascular endothelial cells (HMVEC-Ls; Lonza) were grown in EGM-2 MV medium (Lonza) supplemented with 15% FBS (Invitrogen). HPAECs (Lonza) were grown in EGM-2 medium (Lonza) supplemented with 15% FBS (Invitrogen). Endothelial cells were used at passages 2--6. Human microvascular endothelial cell (HMECs; dermal; Lonza) were grown in MCDB 131 medium (Invitrogen) supplemented with 10% FBS, 0.003 µg/ml h-EGF, 0.001 mg/ml hydrocortisone, and [l]{.smallcaps}-glutamine.

For measurement of basal NO generation, cells were incubated in [l]{.smallcaps}-arginine--free EBM media (Lonza) for 2 h. Cells were treated with 4 µM NPA, 4 µM 1400W, 4 µM [l]{.smallcaps}-NNA, and 100 µM SIN-1 for 30 min; and with 150 U/ml PEG-SOD, 100 µM TEMPOL, 2 µg/ml Rho inhibitor C3 transferase, and 6 µM AP-CSD peptide for 2 h. 70--80% confluent monolayers were transfected using FuGENE HD (Rhoche) and Lipofectamine 2000 (Invitrogen) transfection reagents in accordance with the manufacturer's instructions.

Co-immunoprecipitation and Western blotting
-------------------------------------------

Cells were lysed in modified RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM Na~3~VO~4,~ 10 µg/ml leupeptin, 10 µg/ml aprotinin, and 0.1 mM PMSF). For co-immunoprecipitation experiments, 350 µg of total protein was incubated with 15 µg of antibody at 4°C, and precipitates were collected with protein A/G agarose beads. Densitometry of blots was performed using ImageJ software (National Institutes of Health).

RhoA-GTP pull-down assay
------------------------

RhoA activity was determined by pull-down assays using GST-Rhotekin beads ([@bib23]). Cells were lysed in 50 mM Tris-HCl, pH 7.5, 10 mM MgCl~2~, 0.5 M NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 10 µg/ml leupeptin, 10 µg/ml aprotinin, and 0.1 mM PMSF. Cell lysates were incubated with GST-RBD beads at 4°C and bound proteins were analyzed by Western blotting. 5% of cell lysates were used to detect total RhoA.

NO measurement
--------------

NO formation was measured using porphyrinic NO electrodes ([@bib6]). Electrodes were calibrated using a stock solution of NO-saturated water. The NO electrode was placed onto the cell surface and two additional electrodes were added into the solution to generate a 650-mV potential. The system was coupled to a FAS1 femtostat and a personal computer with electrochemical software (Gamry Instruments). The electrode current, which is proportional to NO concentration, was measured as a function of time.

Nitrite measurement
-------------------

Nitrite accumulation in cell culture media was assessed by a chemiluminescence assay ([@bib5]) using an NO Analyzer (NOA 280i; GE Healthcare). Authentic NaNO~2~ solutions of known concentrations were used as standards. All measurements were performed relative to cell-free controls.

Measurement of intracellular superoxide
---------------------------------------

Cells plated in a 96-well plate were left untreated or incubated with 50 µM BH~4~ or 500 µM [l]{.smallcaps}-arginine for 30 min, then treated with 50 µM DHE for 1 h. Emission of EOH, a product of DHE oxidation, at λ = 580 nm, was measured using a SpectraMax M5e Multi-Mode Microplate Reader (Molecular Devices).

SNO measurement
---------------

SNO content of junctional proteins was detected by biotin-switch method using the S-nitrosylated Detection Assay kit (Cayman Chemical) according to the manufacturer's instructions. The biotin-labeled proteins were precipitated with ice-cold acetone, and 350 µg of total protein was used for co-immunoprecipitation with specific Abs. SNO content was detected with SNO detection reagent I on Western blots. The same blot was reprobed for protein of interest.

Immunofluorescence staining and image analysis
----------------------------------------------

Cell were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100, and stained as described previously ([@bib24]). Samples were mounted with ProLong-Gold antifade reagent (Invitrogen). Z-stack images were obtained using a confocal microscope (LSM 510 Meta; Carl Zeiss) equipped with a 63×, 1.2 NA water immersion objective lens and Ar ion and dual HeNe lasers, and driven by LSM software. 12-bit images were analyzed using MetaMorph software (Molecular Devices) and prepared for illustration in Photoshop (Adobe). Projection images were generated by collecting the maximum pixel intensity from each image of the z stack and by projecting pixel intensity onto the single (projection) image. The relative accumulation of β-catenin (mean fluorescence intensity) at AJs and the area of gaps were measured on projected images. The 12-bit images were thresholded by subtracting intracellular background, and the mean fluorescence intensity at AJs was measured. For measurement of eNOS accumulation at AJs, the corresponding VE-cadherin image was used to generate a binary mask within 0 (outside of AJs) and 1 (AJs area) values after subtracting intracellular background, and the eNOS image was multiplied by a binary mask image for VE-cadherin. The mean fluorescence intensity of eNOS at AJs was then measured as described for β-catenin. Gap area was expressed as a percentage of the area outside of the cell.

Live cell imaging and image processing
--------------------------------------

Cells were imaged in phenol-free EBM media (Lonza) supplemented with 5% FBS at 37°C maintained by the stage heater (Tempcontrol-37; Carl Zeiss). Z-stack images were obtained using a confocal microscope (LSM 510 Meta; Carl Zeiss) equipped with a 63×, 1.2 NA water immersion objective lens and Ar ion and dual HeNe lasers. For emission ratio imaging, we acquired 12-bit CFP (λ = 458 nm; BP500/20), FRET (λ = 458 nm; LP530), and YFP (λ = 514 nm; LP530) images. All images were processed and analyzed using MetaMorph software. The FRET image was used to generate a binary mask within 0--1 values. To generate a ratio image reflecting RhoA activity, the FRET image was first multiplied by a binary mask image and then divided by the CFP image. The ratio images were rescaled to the lower value and a linear pseudocolor table was applied to generate the color-coded image map. The z stack FRET/CFP emission ratio images were used to generate the projection image. The relative RhoA activity was expressed as mean pixel intensity.

Endothelial barrier permeability measurement
--------------------------------------------

The permeability of MLVECs monolayer to EBA was determined as described previously ([@bib33]). Cells were grown to confluence on transwell inserts with a 0.4 µm pore size. Upper (luminal) and lower (abluminal) chambers were filled with HBSS containing 0.5% BSA and 20 mM Hepes. After a 30-min equilibration period, the luminal chamber was loaded with 0.057% EBA. Samples from the abluminal chamber were collected every 5 min for 1 h. EBA concentration was calculated from the optical density measured at 620 nm with the aid of the SpectraMax Plus microplate spectrophotometer (Molecular Devices). The rate of EBA clearance from luminal chamber was determined by linear regression between 5 and 60 min.

Perfusion of mouse lungs and measurement of transvascular fluid filtration
--------------------------------------------------------------------------

Murine lung preparations from WT and *Cav-1*^−/−^ male mice (C57bl/6 strain) were performed according to an approved protocol of the University of Illinois at Chicago Animal Care Committee ([@bib43]). In brief, isolated lung preparations were perfused with RPMI medium at constant flow (2 ml/min), temperature (37°C), and venous pressure (4 cm H~2~O). The preparation was ventilated at a rate of 120 breaths per min, at constant peak inspiratory (∼10 cm H~2~O) and end expiratory pressures (2 cm H~2~O). The lung weight change was recorded by a force-displacement transducer (Model FT03C; Grass Technologies). All lung preparations underwent a 10-min equilibration perfusion to establish isogravimetric conditions followed by a 30-min step change in perfusate albumin concentration (g/100 ml) of albumin from 0 to 10. In some cases, AP-CSD (final concentration of 10 µM) was added into the high-albumin perfusate between minute 20 and 40 from the beginning of perfusion. The fluid filtration rate was obtained by fitting a double exponential growth curve, *y~0~* = *a*(1 *−* *e^−Ka\ t^*) + *b*(1 *−* *e^−Kb\ t^*), to the lung weight gain upon removal of albumin. The fast exponential component, which was of relatively low amplitude and coincident with the change of solution, most likely represented the effect of the shift in solution viscosity. The slow exponential component represented fluid filtration across the vessel wall induced by the change in oncotic pressure. The filtration rate was determined from the initial slope of this component extrapolated to zero time.

Statistical analysis
--------------------

Data handling was performed using Sigma Plot software (SPSS). For statistical analysis, a paired two-tailed Student's *t* test was used to compare data between two groups.

Online supplemental material
----------------------------

Fig. S1 provides a characterization of primary MLVECs. Fig. S2 shows the effect of a Rho inhibitor on phosphorylation of MLC 2 in *Cav-1*^−/−^ endothelium. Table S1 summarizes the parameters of transvascular fluid filtration across the microvessel wall in isolated lungs. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201012129/DC1>.
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